Category: Methimazole

Felixvet Introduces First FDA-Approved Generic Methimazole Tablets for the Treatment of Hyperthyroidism in Cats

Posted on by developer@wearewoodruff.com

Kansas City, Mo. — July 14, 2026 — Felixvet Inc. today announced the commercial availability of Methimazole Coated Tablets, the first FDA-approved generic version of methimazole tablets for the treatment of hyperthyroidism in cats and a therapeutically equivalent alternative to Felimazole®. Approved by the U.S. Food and Drug Administration (FDA) on July 22, 2025, Methimazole Coated Tablets provide veterinarians with a trusted new option for the management of one of the most commonly diagnosed endocrine disorders in feline patients.

Product Details

Two white plastic prescription bottles of Methimazole Coated Tablets for cats, showing a 5 mg strength bottle next to a 2.5 mg strength bottle.
Felixvet Methimazole Coated Tablets are available in 2.5 mg and 5 mg strengths for oral use in cats only. 

“We’re incredibly excited to bring the first FDA-approved generic methimazole tablets to the veterinary market,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels at Felixvet. “Methimazole has been a cornerstone therapy for the management of feline hyperthyroidism for many years, and this approval represents an important opportunity to expand access to a trusted treatment option for veterinarians, pet owners, and the cats they care for.”

Hyperthyroidism is a common endocrine disorder in cats caused by excessive production of thyroid hormones. Clinical signs may include weight loss, increased appetite, increased thirst and urination, vomiting, and hyperactivity. Methimazole Coated Tablets help manage the disease by inhibiting the synthesis of thyroid hormones. 

The FDA approved Methimazole Coated Tablets (ANADA 200-814) after determining the product is bioequivalent to the pioneer drug, Felimazole® (NADA 141-292). The approval followed a comprehensive review of the product’s safety, effectiveness, and manufacturing quality.

Felixvet’s Methimazole Coated Tablets are available in:

  • 2.5 mg coated tablets – 100-count bottles 
  • 5 mg coated tablets – 100-count bottles 

The tablets are film-coated and intended for oral administration in cats. Methimazole Coated Tablets are therapeutically equivalent to the pioneer product and provide veterinarians with an FDA-approved treatment option for the long-term management of feline hyperthyroidism. 

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and distribution partners with high-quality, bioequivalent treatment options across key therapeutic categories.

For additional information, please contact info@felixvet.com

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com

Felixvet Receives FDA Approval for Methimazole Coated Tablets

Posted on by developer@wearewoodruff.com

Kansas City, MO — September 19, 2025 — Felixvet Inc. has received the first FDA generic approval for Methimazole Coated Tablets, an antithyroid drug indicated for the treatment of hyperthyroidism in cats. With this milestone, Felixvet continues to advance its mission of offering high-quality, affordable medications for companion animals. The company established its North American headquarters in Kansas City, Missouri, in 2023 and aims to serve veterinarians, pet owners and distributors alike.

The U.S. Food and Drug Administration approved Methimazole Coated Tablets (ANADA 200-814) after determining the product is bioequivalent to the pioneer drug, Felimazole (NADA 141-292), originally approved in 2009. The approval followed a rigorous review of the drug’s safety and manufacturing quality.

“Felixvet is committed to meeting the clinical needs of veterinarians while offering affordable, reliable alternatives,” said Vince Palasota, President of North America at Felixvet. “Each of our products is developed to the highest regulatory standards to ensure consistency, quality and therapeutic equivalence.”

Hyperthyroidism is most commonly diagnosed in senior felines and results from an overproduction of thyroid hormones that may cause symptoms such as weight loss, increased thirst and urination, vomiting and hyperactivity. Methimazole Coated Tablets help manage this disease by inhibiting the synthesis of thyroid hormones.

Methimazole Coated Tablets are film-coated, which can aid in administration, and are supplied in 2.5 mg and 5 mg strengths for oral use. They are administered every 12 hours with dosage adjustments made in 2.5 mg increments, based on a cat’s response and veterinary guidance.

“Methimazole is an important therapy for managing feline hyperthyroidism, and we’re proud to add it to our growing portfolio,” added Palasota. “We look forward to continuing to deliver solutions that meet the daily needs of veterinarians and their patients.”

Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.

For more information, email info@felixvetus.com.

About Felixvet: 
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 1-816-912-2000
Email: info@felixvetus.com